CliffBio

Guerbet

Patent cliffs & loss of exclusivity

Guerbet is a Tokyo-based company in the pharmaceutical industry.

Company

Company Operating StatusActive
Official Websitehttp://www.guerbet.co.jp/

7 upcoming patent cliffs

DrugIngredientTypeCliff
  1. ELUCIREMGADOPICLENOLSmall mol.Jan 2040
  2. ELUCIREMGADOPICLENOLSmall mol.Jan 2040
  3. ELUCIREMGADOPICLENOLSmall mol.Jan 2040
  4. ELUCIREMGADOPICLENOLSmall mol.Jan 2040
  5. ELUCIREMGADOPICLENOLSmall mol.Jan 2040
  6. ELUCIREMGADOPICLENOLSmall mol.Jan 2040
  7. ELUCIREMGADOPICLENOLSmall mol.Jan 2040
  8. HEXABRIXIOXAGLATE MEGLUMINE; IOXAGLATE SODIUMSmall mol.—
  9. OXILAN-300IOXILANSmall mol.—
  10. OXILAN-350IOXILANSmall mol.—
  11. LIPIODOLETHIODIZED OILSmall mol.—
  12. DOTAREMGADOTERATE MEGLUMINESmall mol.—
  13. DOTAREMGADOTERATE MEGLUMINESmall mol.—
  14. DOTAREMGADOTERATE MEGLUMINESmall mol.—
  15. DOTAREMGADOTERATE MEGLUMINESmall mol.—
  16. DOTAREMGADOTERATE MEGLUMINESmall mol.—

Loss-of-exclusivity dates are derived from the FDA Orange & Purple Books; company detail is from the CliffBio graph. Estimates are projections, not legal advice.

Guerbet — patent cliffs & loss of exclusivity | CliffBio